You are here:

Levodopa, carbidopa and entacapone (Stalevo)

Advice

Following an abbreviated submission Accepted for use in NHSScotland.

Stalevo® for the treatment of patients with Parkinson’s disease and end of dose motor fluctuations not stabilised on levodopa/dopa decarboxylase inhibitor treatment.

This combination preparation allows administration of a single tablet incorporating ingredients that are routinely combined for the indication described above. This may improve convenience to the patient. Depending on the doses and formulations being replaced, conversion to the combination may result in a modest increase in cost or (less commonly) a cost saving.

Drug Details

Drug Name: Levodopa, carbidopa and entacapone (Stalevo)
SMC Drug ID: 85/03
Manufacturer: Orion Pharma (UK) Ltd
Indication: Parkinson's disease and end of dose motor fluctuations not stabilised on levodopa/dopa decarboxylase inhibitor treatment
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 12 January 2004

Back